Researchers propose "exercise mimetics" (exercise pills) to treat depression by hacking the muscle-brain axis for those unable to physically exercise.

Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on ...

Luvesilocin is a subcutaneously-administered, proprietary prodrug of the psilocybin-like compound 4-OH-DiPT designed to target the serotonin 2A receptor.

A Phase IIa clinical trial finds that a single, brief dose of DMT (from ayahuasca) provides rapid and lasting relief for depression.

People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. The findings point toward the possibility of dietary therapies for ...

The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and ...

An AI-based machine learning tool identified depression in 71% of people with the condition from under a minute of free speech. The findings may enable more widespread screening for the condition. The ...

Researchers found that a single 21.5mg dose of DMT reduced depression symptoms compared to placebo in patients with treatment ...

Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...